Article
Hematology
I. Gomez-Segui, E. Frances Aracil, M. E. Mingot-Castellano, M. Vara Pampliega, R. Goterris Viciedo, F. Garcia Candel, C. Pascual Izquierdo, J. del Rio Garma, L. Guerra Dominguez, I. Vicuna Andres, J. Garcia-Arroba Peinado, S. Zalba Marcos, J. M. Vidan Estevez, E. Gonzalez Arias, V. Campuzano Saavedra, J. M. Garcia Gala, S. Ortega Sanchez, J. Martinez Nieto, L. Pardo Gambarte, M. Sole Rodriguez, M. Fernandez-Docampo, L. F. Avila Idrovo, L. Hernandez, J. Cid, J. de la Rubia Comos
Summary: The clinical characteristics and treatment response of immune thrombotic thrombocytopenic purpura (iTTP) in older patients were analyzed and compared with younger patients. Similar symptoms and laboratory results were observed in both groups, but older patients had a higher incidence of renal dysfunction. The frontline treatment and clinical outcomes did not differ between the two age groups. Notably, the use of caplacizumab and rituximab showed favorable safety and efficacy profiles in older patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Andrew J. Doyle, Matthew J. Stubbs, Will Lester, Will Thomas, John-Paul Westwood, Mari Thomas, Charles Percy, Nithya Prasannan, Marie Scully
Summary: Obinutuzumab and ofatumumab may be considered as alternative options to rituximab in the treatment of iTTP, with a comparable safety profile, absence of significant hypersensitivity reactions, and sustained normalization of ADAMTS13.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Hematology
George Goshua, Pranay Sinha, Natalia Kunst, Lauren Pischel, Alfred Ian Lee, Adam Cuker
Summary: This study conducted a cost-effectiveness analysis of second-line therapies in chronic ITP using prospective, observational, and meta-analytic data. The findings suggest that early use of splenectomy and rituximab is the most cost-effective treatment strategy, while early use of TRAs is less cost-effective but yields similar effectiveness.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Cimarron E. Sharon, Richard J. I. I. I. I. I. I. Straker, Nikhita Perry, John T. Miura, Giorgos C. Karakousis
Summary: This study aimed to identify factors associated with 30-day morbidity after splenectomy for ITP and evaluate their impact on 30-day mortality. The results showed low rates of morbidity and mortality, with higher morbidity rates in patients with multiple risk factors. Early splenectomy may be an effective treatment option for low-risk patients.
JOURNAL OF SURGICAL ONCOLOGY
(2022)
Review
Hematology
Asad Riaz, Hossam Tharwat Ali, Fawad Ali, Jawad Ali
Summary: This case report highlights a rare occurrence of recurrent ITP after accessory spleen removal, suggesting that this procedure may not always be effective in treating ITP. Other treatment options, such as bone marrow transplantation, may be necessary in some cases.
CLINICAL HEMORHEOLOGY AND MICROCIRCULATION
(2023)
Review
Medicine, General & Internal
Quan-Li Zhu, Wei Wu
Summary: The clinical efficacy of LS and OS in the treatment of Idiopathic thrombocytopenic purpura is similar, with LS having a longer operative time, less estimated blood loss, and shorter postoperative length of stay compared to OS.
Article
Medicine, Research & Experimental
Hangping Ge, Zhan Shi, Zhiyin Zheng, Qiuping Zhu, Lili Hong, Yu Zhang, Jianping Shen, Shu Deng
Summary: This case report describes a 33-year-old Chinese woman with a history of immune thrombocytopenic purpura who presented with heavy menstrual bleeding. The patient was diagnosed with the coexistence of thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura. After treatment, including plasmapheresis, glucocorticoid, and rituximab, the patient's condition improved and she was discharged.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
(2022)
Review
Hematology
Waleed Ghanima, Terry Gernsheimer, David J. Kuter
Summary: Approximately 80% of adult patients with ITP experience treatment failure with corticosteroids, leading to the need for second-line therapy. New, effective treatments like TPO-RAs and rituximab are recommended, while splenectomy should be delayed to allow remission with medical therapies. Individualized treatment approaches are necessary, as responses to different therapies may vary and re-treatment may be needed in the future.
Article
Hematology
Xiaofan Liu, Hu Zhou, Yu Hu, Jie Yin, Junmin Li, Wenming Chen, Ruibin Huang, Yuping Gong, Chengwei Luo, Heng Mei, Bingjie Ding, Chengyuan Gu, Huiping Sun, Yun Leng, Dexiang Ji, Yan Li, Hongyan Yin, Haiyan Shi, Keyan Chen, Jian Wang, Songhua Fan, Weiguo Su, Renchi Yang
Summary: This study assessed the safety, tolerability, pharmacokinetics, preliminary activity, and recommended phase 2 dose of sovleplenib in patients with primary immune thrombocytopenia. The results showed that sovleplenib was well tolerated and the recommended phase 2 dose demonstrated promising durable response in these patients.
LANCET HAEMATOLOGY
(2023)
Article
Obstetrics & Gynecology
Lu Zhou, Yu Zhu, Miao Jiang, Jian Su, Xiaofan Liu, Yizhi Jiang, Hui Mu, Jie Yin, Li Yang, Haiyan Liu, Weidong Pan, Min Su, Hong Liu
Summary: This study presents a case of a pregnant woman with severe TTP and asymptomatic Sjogren's syndrome. Treatment with rituximab, PEX, and steroids significantly improved the patient's ADAMTS13 enzyme activity. The findings highlight the importance of enzyme-linked immunosorbent assay in the diagnosis and rituximab in the treatment of acquired TTP.
BMC PREGNANCY AND CHILDBIRTH
(2021)
Article
Hematology
Naokazu Nakamura, Hiroko Tsunemine, Tomomi Sakai, Nobuyoshi Arima
Summary: In this retrospective, single-center cohort study, we found that old age (≥81 years), low platelet count (<9 x 10(9)/L), high level of platelet-associated IgG (≥445 ng/10(7)cells), high platelet distribution width (≥14.0 g/dL), high lymphocyte-to-monocyte ratio (≥3.52), and low megakaryocyte count in bone marrow (<85.5/mu l) are reliable biomarkers for predicting poor response to corticosteroid therapy in patients with ITP.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Medicine, General & Internal
Ju-Yang Jung, Ji-Won Kim, Chang-Hee Suh, Hyoun-Ah Kim
Summary: This study describes a 16-year-old girl with SLE and immune thrombocytopenia who was diagnosed with TTP. She was successfully treated with plasmapheresis and rituximab therapy, and her relapse after 18 months was controlled using the same management.
Article
Medicine, Research & Experimental
Pablo Canales-Herrerias, Etienne Crickx, Matteo Broketa, Aurelien Sokal, Guilhem Chenon, Imane Azzaoui, Alexis Vandenberghe, Angga Perima, Bruno Iannascoli, Odile Richard-Le Goff, Carlos Castrillon, Guillaume Mottet, Delphine Sterlin, Ailsa Robbins, Marc Michel, Patrick England, Gael A. Millot, Klaus Eyer, Jean Baudry, Matthieu Mahevas, Pierre Bruhns
Summary: High-affinity autoreactive plasma cells exist in multiple anatomical compartments of patients with ITP, which may result in the failure of current therapies.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Medicine, General & Internal
Toshiki Mushino, Takayuki Hiroi, Yusuke Yamashita, Norihiko Suzaki, Hiroyuki Mishima, Masaki Ueno, Akira Kinoshita, Koichi Minami, Kohsuke Imai, Ko-ichiro Yoshiura, Takashi Sonoki, Shinobu Tamura
Summary: Kabuki syndrome is a rare genetic disorder characterized by multiple systemic anomalies and intellectual disability, often complicated with immune issues. Surgical treatment, such as laparoscopic splenectomy, may be an effective therapeutic option for patients with Kabuki syndrome presenting with immune thrombocytopenic purpura and symptomatic splenomegaly.
Review
Hematology
X. Long Zheng
Summary: For immune thrombotic thrombocytopenic purpura (iTTP), the triple therapy consisting of therapeutic plasma exchange, caplacizumab, and immunosuppressives has been proven to be an effective treatment for acute episodes, accelerating platelet count normalization, reducing ICU and hospital stays, and most importantly, lowering mortality rate.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2021)